Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Researchers develop therapy to treat the rare skin disease ichthyosis

24.06.2013
Drug is ready – but hard to launch: Münster University physicians develop therapy to treat ichthyosis ("fish-scale disease") / No pharmaceutical company found to progress and to market the drug

In the fight against common diseases such as cancer the strategy is clear: scientists are working flat out on research, methods of early detection and treatments. That the demand is enormous is not surprising: according to the Federal Statistics Office, around 26 percent of all deaths in Germany in 2011 were due to cancer. So it is no wonder that patients, researchers and pharmaceutical companies want to see effective drugs developed fast.

But what is the situation with drugs to treat diseases which affect only a few people? “These drugs are often neglected by pharmaceutical companies because they are economically unattractive,” says Dr. Karin Aufenvenne, a biologist, who personally experienced the problem over the past few years. Around one year ago she and Prof. Heiko Traupe, senior physician for dermatology at the skin clinic at Münster University Hospital, achieved a breakthrough in treating a special form of ichthyosis with medication. This highly unpleasant skin disease, often known as fish-scale disease, is caused by genetic defects and occurs directly after birth. Patients suffer from an extreme thickening of the top layer of the skin, which manifests itself in a dark brown, lamellar desquamation covering the entire body. “Around 2,500 people in Europe are estimated to have the disease – which means it is ultra-rare,” says Karin Aufenvenne.

For this reason no pharmaceutical company could be found which was prepared to progress and - above all - market the therapy developed at Münster University (WWU) in close cooperation with the working group headed by Dr. Margitta Dathe at the Leibniz Institute of Molecular Pharmacology (FMP) in Berlin. This situation could, however, change shortly. The reason is that the medication was recently awarded orphan drug status by the European Union – an unprecedented event at WWU and FMP. With the official EU designation as a “drug to treat rare afflictions”, it becomes more economically attractive. “Pharmaceutical companies that buy the rights to such a drug do not have to pay any approval costs, for example,” explains Karin Aufenvenne. “And after regulatory approval they have exclusive rights to the drug for ten years.” In Münster there is a strong desire to find a company attracted by these incentives. “The distress felt by patients who have this disease is enormous – not only due to the physical symptoms, but also because of the mental suffering.”

Get up, have a shower, get dressed and off to work: what for many of us is normal daily life is just not possible for people suffering from ichthyosis. The hornification develops anew every day, which is why those affected with the disease have to bathe thoroughly at least once a day and remove the scales from their body, for example with a pumice stone. To protect the sensitive skin from drying out, patients have to apply a lotion to their whole body several times a day. “Personal hygiene plays a heightened role,” says Karin Aufenvenne, “as the sensitive skin can easily become inflamed, especially in childhood.”
“As a result of the genetic defect,” she explains, “there is an enzyme missing in the body – transglutaminase 1. In the case of healthy people this enzyme acts in the top skin layers. However, if it is missing the natural protective function of the skin is disturbed and the skin loses much more water – which is why scales form over large areas. The substance that we have developed penetrates the skin cells from the outside so that the enzyme can act there.” One of the ways in which the positive effect is shown is through the reduction in the loss of water through the skin. “But the optical effect is also noticeable: the skin normalises itself.”

For people who suffer from ichthyosis, the designation of the therapy developed in Münster as a drug to treat rare afflictions is a ray of hope. The researchers had admittedly already contacted pharmaceutical companies, but as a result of the EU’s designation the situation has improved significantly. There are currently two companies showing a strong interest and negotiations are underway. The Münster scientists are being supported by Clinic Invent, the patents office at the Faculty of Medicine.

Background information: orphan drugs

The term “orphan drug” was first used in 1983 to describe drugs to treat rare diseases. The status of a “drug to treat rare afflictions” is awarded by the EU only if there are fewer than 230,000 patients per year or fewer than five patients for every 10,000 people. Applications are examined by the Committee on Medicines to Treat Rare Diseases, within the European Medicines Agency. If the Committee gives an appropriate recommendation, the EU decides on whether the medicine receives the orphan drug status.

Dr. Christina Heimken | idw
Further information:
http://www.uni-muenster.de/

More articles from Health and Medicine:

nachricht One gene closer to regenerative therapy for muscular disorders
01.06.2017 | Cincinnati Children's Hospital Medical Center

nachricht The gut microbiota plays a key role in treatment with classic diabetes medication
01.06.2017 | University of Gothenburg

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Can we see monkeys from space? Emerging technologies to map biodiversity

An international team of scientists has proposed a new multi-disciplinary approach in which an array of new technologies will allow us to map biodiversity and the risks that wildlife is facing at the scale of whole landscapes. The findings are published in Nature Ecology and Evolution. This international research is led by the Kunming Institute of Zoology from China, University of East Anglia, University of Leicester and the Leibniz Institute for Zoo and Wildlife Research.

Using a combination of satellite and ground data, the team proposes that it is now possible to map biodiversity with an accuracy that has not been previously...

Im Focus: Climate satellite: Tracking methane with robust laser technology

Heatwaves in the Arctic, longer periods of vegetation in Europe, severe floods in West Africa – starting in 2021, scientists want to explore the emissions of the greenhouse gas methane with the German-French satellite MERLIN. This is made possible by a new robust laser system of the Fraunhofer Institute for Laser Technology ILT in Aachen, which achieves unprecedented measurement accuracy.

Methane is primarily the result of the decomposition of organic matter. The gas has a 25 times greater warming potential than carbon dioxide, but is not as...

Im Focus: How protons move through a fuel cell

Hydrogen is regarded as the energy source of the future: It is produced with solar power and can be used to generate heat and electricity in fuel cells. Empa researchers have now succeeded in decoding the movement of hydrogen ions in crystals – a key step towards more efficient energy conversion in the hydrogen industry of tomorrow.

As charge carriers, electrons and ions play the leading role in electrochemical energy storage devices and converters such as batteries and fuel cells. Proton...

Im Focus: A unique data centre for cosmological simulations

Scientists from the Excellence Cluster Universe at the Ludwig-Maximilians-Universität Munich have establised "Cosmowebportal", a unique data centre for cosmological simulations located at the Leibniz Supercomputing Centre (LRZ) of the Bavarian Academy of Sciences. The complete results of a series of large hydrodynamical cosmological simulations are available, with data volumes typically exceeding several hundred terabytes. Scientists worldwide can interactively explore these complex simulations via a web interface and directly access the results.

With current telescopes, scientists can observe our Universe’s galaxies and galaxy clusters and their distribution along an invisible cosmic web. From the...

Im Focus: Scientists develop molecular thermometer for contactless measurement using infrared light

Temperature measurements possible even on the smallest scale / Molecular ruby for use in material sciences, biology, and medicine

Chemists at Johannes Gutenberg University Mainz (JGU) in cooperation with researchers of the German Federal Institute for Materials Research and Testing (BAM)...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Plants are networkers

19.06.2017 | Event News

Digital Survival Training for Executives

13.06.2017 | Event News

Global Learning Council Summit 2017

13.06.2017 | Event News

 
Latest News

Quantum thermometer or optical refrigerator?

23.06.2017 | Physics and Astronomy

A 100-year-old physics problem has been solved at EPFL

23.06.2017 | Physics and Astronomy

Equipping form with function

23.06.2017 | Information Technology

VideoLinks
B2B-VideoLinks
More VideoLinks >>>